Sanofi has completed its sale of a 50% controlling stake in its consumer healthcare business, Opella, to CD&R, an investment firm, for EUR 10 billion ($11.4 billion). 

Following closing, CD&R now has a 50.0% stake in Opella, Sanofi a 48.2% stake, and Bpifrance, a French public sector investment bank, a 1.8% stake. 

Sanofi had first announced that it was in negotiations to sell its controlling stake in Opella to CD&R last October (October 2024). Following completion of required social and corporate procedures, Sanofi and CD&R announced this February (February 19, 2025) that they had signed a share purchase agreement to proceed with the sale.   

Headquartered in France, Opella has over 11,000 employees and operates in 100 countries with 13 manufacturing sites and four science and innovation development centers. Its product portfolio includes over-the-counter products, such as Allegra, Doliprane, and Dulcolax.  

Source: Sanofi